Global Immunology Market to Capitalize on Impressive Product Pipeline

Published Date : Mar 14, 2016

ALBANY, New York, March 14, 2016 – announces the addition of a new report to its repository, titled “Global Immunology Market To 2022 - Large Pipeline And Competitive Market To Drive Long-Term Market Growth.” This is a comprehensive report studying the factors influencing the long-term growth of the global immunology market. The report includes valuable information pertaining to the therapeutic pipeline of immune-mediated inflammatory diseases. It also studies how the ongoing clinical trials are influencing the present dynamics of the global immunology market.

Immune-mediated inflammatory diseases are a common group of chronic disorders that affect almost 5% to 7% of the Western population. Despite being disparate in terms of key patient demographics and disease symptoms, immune-mediated inflammatory ailments are often pathophysiologically linked and are characterized by an inappropriate immune response and dysregulation of immune pathways. Usually, disease-modifying anti-rheumatic drugs, which belong to a highly genericized class of small molecule-based agents, are used in case of the first-line treatment of these diseases. However, if it may require it, the treatment is supplemented by glucocorticoid therapy of a relatively shorter term.

The majority of the therapies administered fail to elicit long-term response. Hence, a prominent second-line therapy segment has emerged in the global immunology market, which began with the approval of Enbrel (etanercept) and Remicade (infliximab) in 1998. This segment mainly encompasses monoclonal antibodies (mAbs), which have proven to be highly successful commercially owing to their widespread use and high costs. Despite the majority of mAbs facing impending patent expiry, the market for immunology is expected to witness persistently rising demand over the forthcoming years.

For Sample Copy, click here:

According to the report, the global immunology market, which in 2015 stood at US$61.5 bn, is expected to reach US$74.2 bn by the end of 2022. If the figures hold true, the global market for immunology will exhibit a meager CAGR of 2.71% between 2015 and 2022.

The report studies the global immunology market from the ground up, covering aspects such as the growth drivers and restraints influencing the market’s trajectory over the forecast period. The therapeutic pipeline of immunology is very large, consisting about 1,838 products in active development. The report studies in detail the gaps in the market being addressed by the most promising products in the late-stage pipeline.

With commercially successful products such as Humira (adalimumab) and Remicade due to lose their patents, the strategies adopted by market players vying to cope with the looming patent expiry of blockbuster drugs are studied in the report in detail.

The report aims to study the patent epidemiology and market revenues generated by the key players in the immunology market across the regional and product segments. It also identifies the commercial opportunities in the immunology deals landscape.

To order report Call Toll Free: 866-997-4948 or send an email on